[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340454-105":59,"doc-detail-340454-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","mathematical-modeling-unveils-optimization-strategies-for-targeted-radionuclide-therapy-of-blood-cancers","Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers","","Targeted radionuclide therapy (TRT) uses injections of cancer-specific molecules linked to radioactive nuclides, but side effects can limit its use, especially in rapidly proliferating, well-perfused organs such as bone marrow. Optimization that accounts for toxicity constraints can improve efficacy. Using experiments in a disseminated multiple myeloma mouse model treated with 225Ac-DOTA-daratumumab, the study develops a mathematical model identifying principles based on nuclide-to-antibody ratio, receptor-capacity dosing, and particle-range–guided multi-dosing.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mathematical-modeling-unveils-optimization-strategies-for-targeted-radionuclide-therapy-of-blood-cancers/340454/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mathematical-modeling-unveils-optimization-strategies-for-targeted-radionuclide-therapy-of-blood-cancers/340454.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is targeted radionuclide therapy (TRT) and why can it be limited by side effects?","Question",{"text":112,"@type":113},"TRT delivers radioactive nuclides conjugated to cancer-specific molecules. Despite targeting, circulating radioconjugates and clearance through liver and kidneys can cause toxicity, particularly to rapidly proliferating, well-perfused organs like bone marrow.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the model recommend optimizing the nuclide-to-antibody ratio?",{"text":117,"@type":113},"The study emphasizes that radioconjugate density on cancer cells determines deposited radiation energy. It proposes using low labeling ratios and reducing accumulation of unlabeled antibodies and decay-associated antibody forms in the bloodstream to mitigate cancer radiation damage from excessive, non-radioactive receptor occupation.",{"name":119,"@type":110,"acceptedAnswer":120},"What role does cancer-binding capacity-based dosing play in improving treatment efficacy?",{"text":121,"@type":113},"Cancer-binding capacity reflects the total number of specific receptors on cancer cells. Avoiding doses that exceed this capacity helps prevent remaining radioconjugates in blood from producing low efficacy-toxicity benefit.",{"name":123,"@type":110,"acceptedAnswer":124},"How can particle range–guided multi-dosing improve TRT outcomes?",{"text":125,"@type":113},"By using short-range particle emitters and high-affinity antibodies, initial dosing can saturate cancer-binding capacity. Subsequent redistribution can then favor viable cells that continue expressing the relevant receptors.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},340454,1790190411,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-24-0306](https://doi.org/10.1158/2767-9764.CRC-24-0306)  OPEN ACCESS  \nMathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers  \nMaxim Kuznetsov1, Vikram Adhikarla1, Enrico Caserta2, Xiuli Wang3, John E. Shively4, Flavia Pichiorri2, and Russell C. Rockne1  \n􀀶  \nABSTRACT  \nTargeted radionuclide therapy (TRT) is based on injections of cancerspecific molecules conjugated with radioactive nuclides. Despite the specificity of this treatment, it is not devoid of side effects limiting its use and is especially harmful for rapidly proliferating organs well perfused by blood, like bone marrow. Optimization of radioconjugate administration accounting for toxicity constraints can increase treatment efficacy. Based on our experiments on a disseminated multiple myeloma mouse model treated by 225Ac-DOTA-daratumumab, we developed a mathematical model, investigation of which highlighted the following principles for optimization of TRT: (i) Nuclide-to-antibody ratio importance. The density of radioconjugates on cancer cells determines the density of radiation energy deposited in them. A low labeling ratio as well as accumulation of unlabeled antibodies and antibodies attached to decay products in the bloodstream can mitigate cancer radiation damage due to excessive occupation of specific receptors by antibodies devoid of  \nradioactive nuclides. (ii) Cancer-binding capacity–based dosing. The total number of specific receptors on cancer cells is a critical factor for treatment optimization, and its estimation may allow increasing treatment efficacy close to its theoretical limit. Injection of doses significantly exceeding cancer-binding capacity should be avoided because radioconjugates remaining in the bloodstream have a negligible efficacy-totoxicity ratio. (iii) Particle range–guided multi-dosing. The use of shortrange particle emitters and high-affinity antibodies can allow for robust treatment optimization via initial saturation of cancer-binding capacity, enabling redistribution of further injected radioconjugates and deposited doses toward still viable cells that continue expressing specific receptors.  \nSignificance: Mathematical modeling yields general principles for optimization of TRT in mouse models of multiple myeloma that can be extrapolated to other cancer models and clinical settings.  \nIntroduction  \nBiological background  \nTargeted therapy is based on suppressing survival and proliferation of cancer cells through interactions with molecules specific to the cancer type under consideration. A large class of targeted agents consists of mAbs that specifically bind to receptors on the surfaces of cancer cells (1). One such example is daratumumab, which targets CD38. These receptors are overexpressed in  \n1Department of Computational and Quantitative Medicine, Beckman Research Institute, City of Hope National Medical Center, Duarte, California. 2Department of Hematologic Malignancies Translational Science, Beckman Research Institute, City of Hope National Medical Center, Duarte, California. 3Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California. 4Department of Immunology and Theranostics, Beckman Research Institute, City of Hope National Medical Center, Duarte, California. Corresponding Author: Maxim Kuznetsov, Beckman Research Institute, City of Hope National Medical Center, 10568 Gateway Promenade, El Monte, CA 91731. [E-mail:](E-mail: mkuznetsov@coh.org)[ mkuznetsov@coh.org](E-mail: mkuznetsov@coh.org)  \ndoi: 10.1158/2767-9764.CRC-24-0306  \nThis open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.  \n©2024 The Authors; Published by the American Association for Cancer Research  \nmultiple myeloma, which is a white blood cell cancer resulting in about 100,000 deaths worldwide annually (2). The main mode o","cbCaimw37kDLuZPH","https://ap.wps.com/l/cbCaimw37kDLuZPH","pdf",4455206,13,"English","# Abstract\n# Introduction\n## Biological background\n# Toxicity and dose-limiting organs","[{\"question\":\"What is targeted radionuclide therapy (TRT) and why can it be limited by side effects?\",\"answer\":\"TRT delivers radioactive nuclides conjugated to cancer-specific molecules. Despite targeting, circulating radioconjugates and clearance through liver and kidneys can cause toxicity, particularly to rapidly proliferating, well-perfused organs like bone marrow.\"},{\"question\":\"How does the model recommend optimizing the nuclide-to-antibody ratio?\",\"answer\":\"The study emphasizes that radioconjugate density on cancer cells determines deposited radiation energy. It proposes using low labeling ratios and reducing accumulation of unlabeled antibodies and decay-associated antibody forms in the bloodstream to mitigate cancer radiation damage from excessive, non-radioactive receptor occupation.\"},{\"question\":\"What role does cancer-binding capacity-based dosing play in improving treatment efficacy?\",\"answer\":\"Cancer-binding capacity reflects the total number of specific receptors on cancer cells. Avoiding doses that exceed this capacity helps prevent remaining radioconjugates in blood from producing low efficacy-toxicity benefit.\"},{\"question\":\"How can particle range–guided multi-dosing improve TRT outcomes?\",\"answer\":\"By using short-range particle emitters and high-affinity antibodies, initial dosing can saturate cancer-binding capacity. Subsequent redistribution can then favor viable cells that continue expressing the relevant receptors.\"}]","Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers | PDF",1790036634,33,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/872296ca7ea249b30638905c089626b5.webp",983,1263,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b8a45168371f01120a9f1f908b3c753c.webp",982,1262,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0026cd104639b1c8ad59d1cf0b7d1bea.webp",981,1261,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5db67db9a778019907373dad6bc72cf.webp",980,1259]